Exposure difference of various dosage forms of mycophenolic acid in different age groups of pediatric kidney transplantation
-
摘要:
目的 探讨儿童肾移植术后服用不同霉酚酸(MPA)制剂在≤12岁与 > 12岁年龄段的暴露差异。 方法 回顾性分析73例接受心脏死亡器官捐献(DCD)儿童肾移植受者的临床资料,术后免疫抑制方案均为MPA+他克莫司+糖皮质激素,按照MPA剂型分为A组(37例,服用吗替麦考酚酯胶囊)、B组(28例,服用麦考酚钠肠溶片)和C组(8例,服用吗替麦考酚酯分散片)。并根据移植时患者年龄分为≤12岁年龄段和 > 12岁年龄段。计算不同药物剂型每日给药剂量,采用酶放大免疫法检测MPA血药浓度(C)与曲线下面积(AUC),比较各组不同时间点和两个年龄段的MPA血药浓度,分析受者术后肾功能恢复情况及并发症发生情况。 结果 A、B、C组给药剂量和各时间点血药浓度比较,差异均无统计学意义(均为P > 0.05)。≤12岁年龄段MPA-C4 h、AUC均高于 > 12岁年龄段,差异均有统计学意义(均为P < 0.05)。B组≤12岁年龄段MPA-C4 h高于 > 12岁年龄段,差异有统计学意义(P=0.016)。B组≤12岁年龄段MPA-C4 h较A组和C组高,但差异无统计学意义(P=0.080)。3组急性排斥反应和感染发生率差异均无统计学意义(均为P > 0.05)。 结论 不同年龄段儿童肾移植术后服用不同MPA制剂有不同的暴露率,≤12岁儿童肾移植受者暴露率较 > 12岁儿童有升高的趋势,但主要表现在服用麦考酚钠肠溶片的受者中。因此,监测MPA的暴露水平是必要的,对调整不同剂型药物用量具有较大的指导意义。 Abstract:Objective To investigate the exposure difference of different dosage forms of mycophenolic acid (MPA) between children aged ≤12 and > 12 years old after kidney transplantation. Methods Clinical data of 73 children undergoing kidney transplantation from donation after cardiac death (DCD) were retrospectively analyzed. Postoperative immunosuppressive regimen was MPA+ tacrolimus+glucocorticoid. According to different dosage forms of MPA, all recipients were divided into group A (n=37, mycophenolate mofetil capsules), group B (n=28, enteric-coated mycophenolate sodium) and group C (n=8, mycophenolate mofetil dispersible tablets). All children were divided into ≤12 and > 12 years old groups according to the age of kidney transplantation. The daily dosage of different dosage forms was calculated. The blood concentration (C) of MPA and the area under the curve (AUC) were detected by enzyme-multiplied immunoassay technique. The MPA blood concentration was statistically compared between two age groups at different time points. The recovery of renal function and postoperative complications were assessed. Results No significant differences were observed in the dosage and blood concentration of drug at different time points among groups A, B and C (all P > 0.05). The MPA-C4 h and AUC in the ≤12 years old group were significantly higher than those in the > 12 years old group (both P < 0.05). In group B, the MPA-C4 h of children aged ≤12 years old was significantly higher compared with that in those aged > 12 years old (P=0.016). The MPA-C4 h of children aged ≤12 years old in group B was higher than those in group A and group C, but the differences were not statistically significant (P=0.080). There was no significant difference in the incidence of acute rejection and infection among three groups (both P > 0.05). Conclusions Children of different ages who are given with different dosage forms of MPA after kidney transplantation obtain different exposure rates. The exposure rate of kidney transplant recipients aged ≤12 years old tends to be higher than that of their counterparts aged > 12 years old, mainly seen in the recipients treated with enteric-coated mycophenolate sodium. Therefore, it is necessary to monitor the exposure level of MPA, which provides significant guidance for adjusting the drug dosage of different dosage forms. -
表 1 3组MPA-AUC及各时间点MPA血药浓度比较
Table 1. Comparison of MPA-AUC and MPA blood concentration at each time point in three groups [M(P25, P75)]
指标 A组(n=37) B组(n=28) C组(n=8) P值 AUC(μg·h/mL) 48.11(32.64,62.86) 49.78(43.52,70.68) 47.02(37.17,61.03) 0.412 C0 h(μg/mL) 2.05(0.89,4.05) −① 2.48(1.26,3.38) 0.854 C1 h(μg/mL) 8.96(4.35,14.01) 4.86(2.27,9.58) 7.34(2.85,9.58) 0.062 C1.5 h(μg/mL) − 6.02(3.29,20.02) − C2 h(μg/mL) 5.59(4.02,8.99) 9.54(4.80,19.50) 4.53(3.67,8.28) 0.108 C4 h(μg/mL) 2.75(2.11,4.81) 3.15(2.44,6.11) 2.75(2.07,3.62) 0.492 注:①−为无数据。 表 2 各组不同年龄段各药物剂型MPA血药浓度比较
Table 2. Comparison of MPA blood concentrations of different dosage forms among each group at different age [M(P25, P75)]
组别 C2 h(μg/mL) C4 h(μg/mL) AUC(μg·h/mL) ≤12岁 > 12岁 ≤12岁 > 12岁 ≤12岁 > 12岁 A组 6.20(3.34,13.91) 5.59(4.70,8.41) 3.49(2.27,4.58) 2.60(2.08,5.04) 53.20(34.91,73.12) 41.29(32.20,58.29) B组 10.02(5.93,19.16) 9.06(2.82,20.00) 5.78(2.71,8.20) 2.65(1.85,3.79) 55.04(46.86,98.57) 47.55(40.11,49.95) C组 4.05(3.23,7.59) 7.48(4.73,8.54) 2.89(1.93,5.06) 2.61(2.04,3.68) 50.42(35.49,57.63) 43.62(37.06,68.43) P值 0.116 0.646 0.080 0.916 0.129 0.738 -
[1] HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2016 annual data report: kidney[J]. Am J Transplant, 2018, 18(Suppl 1): 18-113. DOI: 10.1111/ajt.14557. [2] BENJANUWATTRA J, PRUKSAKORN D, KOONRUNGSESOMBOON N. Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications[J]. J Clin Pharmacol, 2020, 60(3): 295-311. DOI: 10.1002/jcph.1565. [3] 曹懿睿, 贾亦臣. 霉酚酸类药物在器官移植受者中的药代动力学研究进展[J]. 器官移植, 2020, 11(5): 635-645. DOI: 10.3969/j.issn.1674-7445.2020.05.018.CAO YR, JIA YC. Research progress on pharmacokinetics of mycophenolic acid drugs in organ transplant recipients[J]. Organ Transplant, 2020, 11(5): 635-645. DOI: 10.3969/j.issn.1674-7445.2020.05.018. [4] FILLER G, ALVAREZ-ELÍAS AC, MCINTYRE C, et al. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy[J]. Pediatr Nephrol, 2017, 32(1): 21-29. DOI: 10.1007/s00467-016-3352-2. [5] BRAZEAU D, MEANEY CJ, CONSIGLIO JD, et al. Association of ABCC2 haplotypes to mycophenolic acid pharmacokinetics in stable kidney transplant recipients[J]. J Clin Pharmacol, 2021, 61(12): 1592-1605. DOI: 10.1002/jcph.1932. [6] BERGAN S, BRUNET M, HESSELINK DA, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology[J]. Ther Drug Monit, 2021, 43(2): 150-200. DOI: 10.1097/FTD.0000000000000871. [7] GUO M, WANG ZJ, YANG HW, et al. Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation[J]. Curr Drug Metab, 2018, 19(14): 1199-1205. DOI: 10.2174/1389200219666171227201608. [8] YOO EC, ALVAREZ-ELÍAS AC, TODOROVA EK, et al. Developmental changes of MPA exposure in children[J]. Pediatr Nephrol, 2016, 31(6): 975-982. DOI: 10.1007/s00467-015-3303-3. [9] BUDDE K, GLANDER P, KRÄMER BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes[J]. Transplantation, 2007, 83(4): 417-424. DOI: 10.1097/01.tp.0000251969.72691.ea. [10] SOBIAK J, RESZTAK M. A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration-time curve estimation[J]. Eur J Drug Metab Pharmacokinet, 2021, 46(6): 721-742. DOI: 10.1007/s13318-021-00713-0. [11] BROOKS EK, TETT SE, ISBEL NM, et al. Evaluation of multiple linear regression-based limited sampling strategies for enteric-coated mycophenolate sodium in adult kidney transplant recipients[J]. Ther Drug Monit, 2018, 40(2): 195-201. DOI: 10.1097/FTD.0000000000000486. [12] BAUER AC, FRANCO RF, MANFRO RC. Immunosuppression in kidney transplantation: state of the art and current protocols[J]. Curr Pharm Des, 2020, 26(28): 3440-3450. DOI: 10.2174/1381612826666200521142448. [13] TETT SE, SAINT-MARCOUX F, STAATZ CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure[J]. Transplant Rev (Orlando), 2011, 25(2): 47-57. DOI: 10.1016/j.trre.2010.06.001. [14] FERREIRA PCL, THIESEN FV, PEREIRA AG, et al. A short overview on mycophenolic acid pharmacology and pharmacokinetics[J]. Clin Transplant, 2020, 34(8): e13997. DOI: 10.1111/ctr.13997. [15] 曾维胜, 张长升, 宋秘, 等. 吗替麦考酚酯与麦考酚钠肠溶片对肾移植受体血药浓度的影响[J]. 器官移植, 2018, 9(6): 436-440. DOI: 10.3969/j.issn.1674-7445.2018.06.007.ZENG WS, ZHANG CS, SONG M, et al. Effect of mycophenolate mofetil and enteric-coated mycophenolate sodium on blood concentration in renal transplantrecipients[J]. Organ Transplant, 2018, 9(6): 436-440. DOI: 10.3969/j.issn.1674-7445.2018.06.007. [16] 王娟, 王丽彬, 郭苗, 等. 霉酚酸在肾移植患者中有限采样法监测方案的探讨[J]. 药学与临床研究, 2019, 27(6): 445-448.WANG J, WANG LB, GUO M, et al. Investigation on monitoring scheme of mycophenolic acid in renal transplant recipients by limited sampling methods[J]. Pharm Clin Res, 2019, 27(6): 445-448. [17] RONG Y, JUN H, KIANG TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients[J]. Br J Clin Pharmacol, 2021, 87(4): 1730-1757. DOI: 10.1111/bcp.14590. [18] ZHANG HX, SHENG CC, LIU LS, et al. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus[J]. Br J Clin Pharmacol, 2019, 85(4): 746-761. DOI: 10.1111/bcp.13850. [19] RESZTAK M, SOBIAK J, CZYRSKI A. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies[J]. Pharmaceutics, 2021, 13(12): 1991. DOI: 10.3390/pharmaceutics13121991. [20] 刘爽, 张恩瑶, 易湛苗, 等. 中国霉酚酸治疗药物监测的现状分析[J]. 中国临床药理学杂志, 2021, 37(3): 308-311. DOI: 10.13699/j.cnki.1001-6821.2021.03.025.LIU S, ZHANG EY, YI ZM, et al. Analysis for the current status of mycophenolic acid therapeutic drug monitoring in China[J]. Chin J Clin Pharmacol, 2021, 37(3): 308-311. DOI: 10.13699/j.cnki.1001-6821.2021.03.025. [21] 杨青彦, 王长安, 韩健乐, 等. 霉酚酸浓度监测对肾移植受者移植后感染的预测价值分析[J]. 医药论坛杂志, 2020, 41(11): 81-84.YANG QY, WANG CA, HAN JL, et al. Predictive value of mycophenolic acid concentration monitoring in renal transplant recipients after transplantation[J]. J Med Forum, 2020, 41(11): 81-84. [22] CHAKRABARTI K, FRAME D, AL ABBAS M, et al. The use of mycophenolate mofetil area under the curve[J]. Curr Opin Rheumatol, 2021, 33(3): 221-232. DOI: 10.1097/BOR.0000000000000799. [23] 郑晓洁, 李思泽, 袁雅文, 等. 儿童生理药代动力学模型及其在儿科药物研究中的应用[J]. 药学学报, 2020, 55(1): 38-44. DOI: 10.16438/j.0513-4870.2019-0594.ZHENG XJ, LI SZ, YUAN YW, et al. Physiologically based pharmacokinetic modeling for children and its application in pediatric drug research[J]. Acta Pharm Sin, 2020, 55(1): 38-44. DOI: 10.16438/j.0513-4870.2019-0594. [24] LIM SY, PETTIT RS. Pharmacokinetic considerations in pediatric pharmacotherapy[J]. Am J Health Syst Pharm, 2019, 76(19): 1472-1480. DOI: 10.1093/ajhp/zxz161. [25] FUKUDA T, GOEBEL J, COX S, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients[J]. Ther Drug Monit, 2012, 34(6): 671-679. DOI: 10.1097/FTD.0b013e3182708f84. [26] JOHNSON TN, TANNER MS, TAYLOR CJ, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis[J]. Br J Clin Pharmacol, 2001, 51(5): 451-460. DOI: 10.1046/j.1365-2125.2001.01370.x. [27] KRALL P, YAÑEZ D, ROJO A, et al. CYP3A5 and UGT1A9 polymorphisms influence immunosuppressive therapy in pediatric kidney transplant recipients[J]. Front Pharmacol, 2021, 12: 653525. DOI: 10.3389/fphar.2021.653525. [28] SCHIAVONE S, NERI M, POMARA C, et al. Personalized medicine in the paediatric population: the balance between pharmacogenetic progress and bioethics[J]. Curr Pharm Biotechnol, 2017, 18(3): 253-262. DOI: 10.2174/1389201018666170207130236. [29] DE WINTER BC, MATHOT RA, SOMBOGAARD F, et al. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring[J]. Clin J Am Soc Nephrol, 2011, 6(3): 656-663. DOI: 10.2215/CJN.05440610. [30] HEBERT SA, SWINFORD RD, HALL DR, et al. Special considerations in pediatric kidney transplantation[J]. Adv Chronic Kidney Dis, 2017, 24(6): 398-404. DOI: 10.1053/j.ackd.2017.09.009. [31] SCHIJVENS AM, DE WILDT SN, SCHREUDER MF. Pharmacokinetics in children with chronic kidney disease[J]. Pediatr Nephrol, 2020, 35(7): 1153-1172. DOI: 10.1007/s00467-019-04304-9. [32] BERGER I, HAUBRICH K, ENSOM MHH, et al. RELATE: relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients[J]. Pediatr Transplant, 2019, 23(2): e13355. DOI: 10.1111/petr.13355. [33] EHREN R, SCHIJVENS AM, HACKL A, et al. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion[J]. Expert Opin Drug Metab Toxicol, 2021, 17(2): 201-213. DOI: 10.1080/17425255.2021.1843633. [34] 邵琨, 陆佳倩, 安会敏, 等. 有限采样法估算中国肾移植受者霉酚酸体内暴露[J]. 中国药师, 2018, 21(9): 1522-1527, 1530. DOI: 10.3969/j.issn.1008-049X.2018.09.004.SHAO K, LU JQ, AN HM, et al. Exposure estimation of mycophenolic acid in Chinese renal transplant recipients by limited sampling strategy[J]. China Pharm, 2018, 21(9): 1522-1527, 1530. DOI: 10.3969/j.issn.1008-049X.2018.09.004. [35] 张丽娟, 陈璐, 朱宇轩, 等. 有限采样法用于肾移植受者霉酚酸酯血药浓度监测的分析[J]. 中国生化药物杂志, 2016, 36(7): 187-190. DOI: 10.3969/j.issn.1005-1678.2016.07.57.ZHANG LJ, CHEN L, ZHU YX, et al. Use of limited sampling strategy to analyse MMF blood concentration in renal transplant recipients[J]. Chin J Biochem Pharma, 2016, 36(7): 187-190. DOI: 10.3969/j.issn.1005-1678.2016.07.57.